Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared Grupo GETNE’s post on X, adding:
“The FDA has granted Orphan Drug Designation to the DLL3-targeting ADC zocilurtatug pelitecan (Zoci) for neuroendocrine carcinomas (NECs).”
Quoting Grupo GETNE’s post:
“An important step toward expanding targeted treatment options in this high unmet-need disease.”
You can also read:
Sergey Badalyan: A Refreshingly Real Talk on Managing Neuroendocrine Carcinoma Beyond the Guidelines
